Diligence memo · auto-generated · as of July 3, 2026
Kiadis Pharma N.V.
Kiadis Pharma N.V. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Kiadis Pharma N.V. operates in Biotechnology, based in AMSTERDAM.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Kiadis Pharma N.V. has raised $18M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $18M on 2019-06-05.
Most recent recorded round closed around 2019-06-05.
Valuation (modeled)modeled
Provath models Kiadis Pharma N.V. at approximately $728M (range $37M–$2.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.18× the median modeled value of Series B Biotechnology companies in 2019–2021 (118 peers) — value vs value, same stage and era. Within the normal band (118% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 7.1 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 66% of Biotechnology peers (4293 compared).
Modeled value ranks above 86% of those peers.
Closest niche peers: Pandion Therapeutics Holdco LLC, Ocular Therapeutix, Inc, Insilico Medicine Cayman TopCo, Purigen Biosystems, Inc., Lucira Health, Inc..
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.